Clinical genomics
Solid Tumor Genomics
Somatic molecular profiling for solid tumours.
Somatic profiling characterises alterations acquired by a tumour. Results support treatment selection and molecular classification, and are reported for the tumour sample analysed rather than for the patient’s inherited genome.
Documented capability
- DNA-based somatic next-generation sequencing of solid tumours
- RNA-based analysis for clinically relevant gene fusions
- Reporting of clinically relevant somatic variants and fusions
- Tumour BRCA1/2 analysis from tumour tissue
- Correlation of somatic findings with the clinical and pathological context
Tumour BRCA1/2 analysis is performed on tumour tissue and reports the tumour’s somatic status. It does not replace germline BRCA1/2 testing, and a tumour finding does not by itself establish an inherited predisposition. Where an inherited cause is suspected, separate germline testing is required — see Hereditary Cancer Genomics.
This page is informational. It does not accept requests, samples, patient data or genomic files, and provides no result lookup.